5-fluorouracil + cisplatin + vindesine

This drug is a combination chemotherapy regimen consisting of three agents: - **5-Fluorouracil (5-FU)** is a pyrimidine analog antimetabolite that inhibits DNA synthesis by blocking thymidylate synthetase, leading to disruption of cancer cell replication. - **Cisplatin** is a platinum-based alkylating agent that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. - **Vindesine** is a vinca alkaloid that inhibits microtubule formation, disrupting mitosis and causing cell death. The combination aims to produce synergistic anticancer effects by targeting different mechanisms involved in cancer cell proliferation. It has been used primarily for treatment of advanced non-small cell lung cancer (NSCLC) and other malignancies. The regimen can be associated with significant toxicities including cardiac toxicity and myelosuppression. Administration typically involves intravenous infusion with dosing schedules designed to optimize efficacy while managing side effects.